Tag: clinical-stage company
-
Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors
ROCHESTER, Minn. — yriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company’s board of directors.